CONDITIONAL MARKETING AUTHORIZATION, COMPASSIONATE USE, AND NAMED PATIENT SUPPLY
In view of the current endeavours to develop vaccines or medicines against Covid-19, this pandemic raises the question of when these products will be available for fighting the disease. More specifically: Will these products have to go through the same lengthy marketing authorization procedures as do other medicinal products, or are there any faster ways to bring these products to use?
In order to find out more, please open the attached file.
